Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials

Lancet

Volumn 365, Issue 9472, 2005, Pages 1687-1717

  Abe, O ^a,by   Abe, R ^a   Enomoto, K ^a   Kikuchi, K ^a,by   Koyama, H ^a   Masuda, H ^a   Nomura, Y ^a,ck   Sakai, K ^a   Sugimachi, K ^a   Tominaga, T ^a   Uchino, J ^a   Yoshida, M ^a   Haybittle, J L ^b   Davies, C ^c,ae   Harvey, V J ^d   Holdaway, T M ^d   Kay, R G ^d   Mason, B H ^d   Forbes, J F ^e   Wilcken, N ^e   Gnant, M ^f   Jakesz, R ^f   Ploner, M ^f   Yosef, H M A ^g   Focan, C ^h   Lobelle, J P ^h   Peek, U ⁱ   Oates, G D ^j   Powell, J ^j   Durand, M ^k   Mauriac, L ^k   Di Leo, A ^l   Dolci, S ^l   Piccart, M J ^l   Masood, M B ^m   Parker, D ^m   Price, J J ^m   Hupperets, P S G J ⁿ   Jackson, S ^o   Ragaz, J ^o   Berry, D ^p   Broadwater, G ^p   Cirrincione, C ^p   Muss, H ^p   Norton, L ^p,ce   Weiss, R B ^p   Abu Zahra, H T ^q   Portnoj, S M ^r   Baum, M ^s,cm   Cuzick, J ^s   Houghton, J ^s   Riley, D ^s   Gordon, N H ^t   Davis, H L ^u   Beatrice, A ^v   Mihura, J ^v   Naja, A ^v   Lehingue, Y ^w   Romestaing, P ^w   Dubois, J B ^x   Delozier, T ^y   Mace Lesec'h, J ^y   Rambert, P ^z   Andrysek, O ^aa   Barkmanova, J ^aa   Owen, J R ^ab   Meier, P ^ac   Howell, A ^ad   Ribeiro, G C ^ad   Swindell, R ^ad,cp   Alison, R ^ae   Boreham, J ^ae,dx   Clarke, M ^ae   Collins, R ^ae   Darby, S ^ae   Elphinstone, P ^ae   Evans, V ^ae   Godwin, J ^ae   Gray, R ^ae,am   Harwood, C ^ae   Hicks, C ^ae   James, S ^ae   MacKinnon, E ^ae   McGale, P ^ae   McHugh, T ^ae   Mead, G ^ae   Peto, R ^ae,dx   Wang, Y ^ae   Albano, J ^af   De Oliveira, C F ^af   Gervasio H ^af   Gordilho, J ^af   Johansen, H ^ag   Mouridsen, H T ^ag,ai   Gelman, R S ^ah   Harris, J R ^ah   Henderson, I C ^ah   Shapiro, C L ^ah   Andersen, K W ^ai   Axelsson, C K ^ai   Blichert Toft, M ^ai   Moller S ^ai   Overgaard, J ^ai   Overgaard, M ^ai   Rose, C ^ai   Carstensen, B ^aj   Palshof, T ^aj   Trampisch, H J ^ak   Dalesio, O ^al   De Vries, E G E ^al   Rodenhuis, S ^al   Van Tinteren, H ^al   Comis, R L ^am   Davidson, N E ^am   Robert, N ^am   Sledge, G ^am   Tormey, D C ^am   Wood, W ^am   Cameron, D ^an   Chetty, U ^an   Forrest, P ^an   Jack, W ^an   Rossbach, J ^ao   Klijn, J G M ^ap   Treurniet Donker, A D ^ap   Van Putten, W L J ^ap   Costa, A ^aq   Veronesi, U ^aq   Bartelink, H ^ar   Duchateau, L ^ar   Legrand, C ^ar   Sylvester, R ^ar   Van Der Hage, J A ^ar   Van De Velde, C J H ^ar   Cunningham, M P ^as   Catalano, R ^at   Creech, R H ^at   Bonneterre, J ^au   Fargeot, P ^au   Fumoleau, P ^au   Kerbrat, P ^au   Namer, M ^au   Jonat, W ^av   Kaufmann, M ^av,bh   Schumacher, M ^av,aw   Von Minckwitz, G ^av   Bastert, G ^aw   Rauschecker, H ^aw   Sauer, R ^aw   Sauerbrei, W ^aw   Schauer, A ^aw   De Schryver, A ^ax   Vakaet, L ^ax   Belfiglio, M ^ay   Nicolucci, A ^ay   Pellegrini, F ^ay   Sacco, M ^ay   Valentini, M ^ay   McArdle, C S ^az   Smith, D C ^az   Galligioni, E ^ba   Boccardo, F ^bb   Rubagotti, A ^bb   Dent, D M ^bc   Gudgeon, C A ^bc   Hacking, A ^bc,di   Erazo, A ^bd   Medina, J Y ^bd   Izuo, M ^be   Morishita, Y ^be   Takei, H ^be   Fentiman, I S ^bf   Hayward, J L ^bf   Rubens, R D ^bf   Skilton, D ^bf   Graeff, H ^bg   Janicke F ^bg   Meisner, C ^bg   Scheurlen, H ^bh   Von Fournier, D ^bh   Dafni, U ^bi   Fountzilas, G ^bi   Klefstrom, P ^bj   Blomqvist, C ^bk   Saarto, T ^bk   Margreiter, R ^bl   Asselain, B ^bm   Salmon, R J ^bm   Vilcoq, J R ^bm   Arriagada, R ^bn   Hill, C ^bn   Laplanche, A ^bn   Le M G ^bn   Spielmann, M ^bn   Bruzzi, P ^bo   Montanaro, E ^bo   Rosso, R ^bo   Sertoli, M R ^bo   Venturini, M ^bo   Amadori, D ^bp   Benraadt, J ^bq   Kooi, M ^bq   Van De Velde, A O ^bq   Van Dongen, J A ^bq   Vermorken, J B ^bq   Castiglione, M ^br,dr,ds   Cavalli, F ^br   Coates, A ^br   Collins, J ^br   Forbes, J ^br   Gelber, R D ^br   Goldhirsch, A ^br,dr,ds   Lindtner, J ^br   Price, K N ^br   Rudenstam, C M ^br   Senn, H J ^br,dr,ds   Bliss, J M ^bs   Chilvers, C E D ^bs   Coombes, R C ^bs   Hall, E ^bs   Marty, M ^bs   Borovik, R ^bt   Brufman, G ^bt   Hayat, H ^bt   Robinson, E ^bt   Wigler, N ^bt   Bonadonna, G ^bu   Camerini, T ^bu   De Palo, G ^bu   Del Vecchio, M ^bu   Formelli, F ^bu   Valagussa, P ^bu   Martoni, A ^bv   Pannuti, F ^bv   Cocconi, G ^bw,cz   Colozza, A ^bw   Camisa, R ^bw   Aogi, K ^bx   Takashima, S ^bx   Ikeda, T ^by   Inokuchi, K ^by   Sawa, K ^by,cx   Sonoo, H ^bz   Korzeniowski, S ^ca   Skolyszewski, J ^ca   Ogawa, M ^cb   Yamashita, J ^cb   Bonte, J ^cc   Christiaens, R ^cc   Paridaens, R ^cc   Van Den Boegart, W ^cc   Martin, P ^cd   Romain, S ^cd   Hakes, T ^ce   Hudis, C A ^ce   Wittes, R ^ce   Giokas, G ^cf   Kondylis, D ^cf   Lissaios, B ^cf   De La Huerta, R ^cg   Sainz, M G ^cg   Altemus, R ^ch   Cowan, K ^ch   Danforth, D ^ch   Lichter, A ^ch   Lippman, M ^ch   O'Shaughnessy, J ^ch   Pierce, L J ^ch   Steinberg, S ^ch   Venzon, D ^ch   Zujewski, J A ^ch   Paradiso, A ^ci   De Lena, M ^ci   Schittulli, F ^ci   Myles, J D ^cj   Pater, J L ^cj   Pritchard, K I ^cj,dv,dw   Anderson, S ^cl   Bass, G ^cl   Brown, A ^cl   Bryant, J ^cl   Costantino, J ^cl   Dignam, J ^cl   Fisher, B ^cl   Redmond, C ^cl   Wieand, S ^cl   Wolmark, N ^cl   Jackson, I M ^cm   Palmer, M K ^cm   Ingle, J N ^cn   Suman, V J ^cn   Bengtsson, N O ^co   Jonsson, H ^co   Larsson, L G ^co   Lythgoe, J P ^cp   Kissin, M ^cq   Erikstein, B ^cr,cs   Hannisdal, E ^cr   Jacobsen, A B ^cr,cs   Varhaug, J E ^cr   Gundersen, S ^cs   Hauer Jensen, M ^cs   Host H ^cs,di   Nissen Meyer, R ^cs,dk   Blamey, R W ^ct   Mitchell, A K ^ct   Morgan, D A L ^ct   Robertson, J F R ^ct   Di Palma, M ^cu   Mathe G ^cu   Misset, J L ^cu   Clark, R M ^cv   Levine, M ^cv   Morimoto, K ^cw   Takatsuka, Y ^cx   Crossley, E ^cy   Harris, A ^cy   Talbot, D ^cy   Taylor, M ^cy   Di Blasio, B ^cz   Ivanov, V ^da   Semiglazov, V ^da   Brockschmidt, J ^db   Cooper, M R ^db   Ueo, H ^dc   Falkson, C I ^dd   A'Hern, R ^de   Ashley, S ^de   Powles, T J ^de   Smith, I E ^de   Yarnold, J R ^de   Gazet, J C ^df   Corcoran, N ^dg   Deshpande, N ^dh   Di Martino, L ^dh   Douglas, P ^di   Lindtner, A ^di   Notter, G ^di   Bryant, A J S ^dj   Ewing, G H ^dj   Firth, L A ^dj   Krushen Kosloski, J L ^dj   Foster, L ^dl   George, W D ^dl   Stewart, H J ^dl   Stroner, P ^dl   Malmstrom P ^dm   Moller T R ^dm   Ryden S ^dm   Tengrup, I ^dm   Tennvall Nittby, L ^dm   Carstenssen, J ^dn   Dufmats, M ^dn   Hatschek, T ^dn   Nordenskjold B ^dn   Soderberg M ^dn   Carpenter, J T ^do   Albain, K ^dp   Crowley, J ^dp   Green, S ^dp   Martino, S ^dp   Osborne, C K ^dp   Ravdin, P M ^dp   Glas, U ^dq   Johansson, U ^dq   Rutqvist, L E ^dq   Singnomklao, T ^dq   Wallgren, A ^dq   Maibach, R ^dr,ds   Thurlimann B ^dr,ds   Brenner, H ^dt   Hercbergs, A ^dt   Yoshimoto, M ^du   DeBoer, G ^dv   Paterson, A H G ^dv   Meakin, J W ^dw   Panzarella, T ^dw   Shan, Y ^dx   Shao, Y F ^dx   Wang, X ^dx   Zhao, D B ^dx   Chen, Z M ^dx   Pan, H C ^dx   Bahi, J ^dy   Reid, M ^dz   Spittle, M ^dz   Deutsch, G P ^ea   Senanayake, F ^ea   Kwong, D L W ^ea   Bianco, A R ^eb   Carlomagno, C ^eb   De Laurentiis, M ^eb   De Placido, S ^eb   Buzdar, A U ^ec   Smith, T ^ec   Bergh, J ^ed   Holmberg, L ^ed   Liljegren, G ^ed   Nilsson, J ^ed   Seifert, M ^ee   Sevelda, P ^ee   Zielinsky, C C ^ee   Buchanan, R B ^ef   Cross, M ^ef   Royle, G T ^ef   Dunn, J A ^eg   Hills, R K ^eg   Lee, M ^eg   Morrison, J M ^eg   Spooner, D ^eg   Litton, A ^eh   Chlebowski, R T ^ei   Caffier, H ^ej   more..

^a ACETBC   (Japan)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c ATLAS Trial Collaborative Study Group   (United Kingdom)

^d Auckland Breast Cancer Study Group   (New Zealand)

^e Australian New Zealand Breast Cancer Trials Group   (Australia)

^f Austrian Breast Cancer Study Group   (Austria)

^g BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^h Belgian Adjuvant Breast Cancer Project   (Belgium)

ⁱ Berlin Brandenburgische Akademie der Wissenschaften   (Germany)

^j Birmingham General Hospital   (United Kingdom)

^k INSTITUT BERGONIÉ   (France)

^l JULES BORDET INSTITUTE   (Belgium)

^m BRADFORD ROYAL INFIRMARY   (United Kingdom)

ⁿ Maastricht UMC+ Comprehensive Cancer Centre   (Netherlands)

^o BRITISH COLUMBIA CANCER AGENCY   (Canada)

^p Cancer and Leukemia Group B   (United States)

^q CANCER CARE ONTARIO   (Canada)

^r INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

^s IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^t CASE WESTERN RESERVE UNIVERSITY   (United States)

^u Central Oncology Group   (United States)

^v INSTITUT CLAUDIUS REGAUD   (France)

^w CENTRE LÉON BÉRARD   (France)

^x CENTRE VAL D AURELLE   (France)

^y François Baclesse Center   (France)

^z CENTRE RENÉ HUGUENIN   (France)

^aa CHARLES UNIVERSITY   (Czech Republic)

^ab CHELTENHAM GENERAL HOSPITAL   (United Kingdom)

^ac UNIVERSITY OF CHICAGO   (United States)

^ad CHRISTIE HOSPITAL   (United Kingdom)

^ae CLINICAL TRIAL SERVICE UNIT   (United Kingdom)

^af Instituto Portugues de Oncologia Francisco Gentil Centro Regional de Oncologia de Coimbra SA   (Portugal)

^ag Back Center of Copenhagen   (Denmark)

^ah DANA FARBER CANCER INSTITUTE   (United States)

^ai Danish Breast Cancer Cooperative Group   (Denmark)

^aj Danish Cancer Registry   (Denmark)

^ak HEINRICH HEINE UNIVERSITY   (Germany)

^al Dutch Working Party for Autologous Bone Marrow Transplant in Solid Tumours   (Netherlands)

^am Eastern Cooperative Oncology Group   (United States)

^an Edinburgh Breast Unit   (United Kingdom)

^ao Diakonie Klinikum Hamburg   (Germany)

^ap ERASMUS MEDICAL CENTER   (Netherlands)

^aq EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^ar EORTC DATA CENTER   (Belgium)

^as EVANSTON HOSPITAL   (United States)

^at FOX CHASE CANCER CENTER   (United States)

^au French Adjuvant Study Group (GFEA)   (France)

^av German Adjuvant Breast Group (GABG)   (Germany)

^aw German Breast Cancer Study Group (BMFT)   (Germany)

^ax GHENT UNIVERSITY HOSPITAL   (Belgium)

^ay GIVIO Interdisciplinary Group for Cancer Care Evaluation   (Italy)

^az VICTORIA INFIRMARY   (United Kingdom)

^ba Gruppo Oncologico Clinico Cooperativo del Nord Est   (Italy)

^bb Gruppo Ricerca Ormono Chemio Terapia Adiuvante (GROCTA)   (Italy)

^bc UNIVERSITY OF CAPE TOWN   (South Africa)

^bd Guadalajara Hospital de 20 Noviembre   (Mexico)

^be GUNMA UNIVERSITY   (Japan)

^bf GUY S HOSPITAL   (United Kingdom)

^bg UNIVERSITY OF HAMBURG   (Germany)

^bh UNIVERSITY OF HEIDELBERG   (Germany)

^bi Hellenic Cooperative Oncology Group   (Greece)

^bj Helsinki Deaconess Medical Centre   (Finland)

^bk UNIVERSITY OF HELSINKI   (Finland)

^bl UNIVERSITY OF INNSBRUCK   (Austria)

^bm INSTITUT CURIE   (France)

^bn INSTITUT GUSTAVE ROUSSY   (France)

^bo UNIVERSITY OF GENOA   (Italy)

^bp ISTITUTO ONCOLOGICO ROMAGNOLO   (Italy)

^bq Integraal Kankercentrum   (Netherlands)

^br International Breast Cancer Study Group (Ludwig)   (Switzerland)

^bs CHARING CROSS HOSPITAL   (United Kingdom)

^bt Israel NSABC   (Israel)

^bu NATIONAL CANCER INSTITUTE   (Italy)

^bv Italian Cooperative Chemo Radio Surgical Group   (Italy)

^bw Italian Oncology Group for Clinical Research   (Italy)

^bx Japanese National Hospitals Group Breast Cancer Study Group   (Japan)

^by Japanese Foundation for Multidisciplinary Treatment of Cancer   (Japan)

^bz KAWASAKI MEDICAL SCHOOL   (Japan)

^ca INSTITUTE OF ONCOLOGY   (Poland)

^cb KUMAMOTO UNIVERSITY   (Japan)

^cc Leuven Akademisch Ziekenhuis   (Belgium)

^cd Serv Ctrl Pharm et du Medicament   (France)

^ce MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^cf METAXA CANCER HOSPITAL   (Greece)

^cg Mexican National Medical Centre   (Mexico)

^ch NATIONAL CANCER INSTITUTE   (United States)

^ci NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^cj Queen's Cancer Research Institute   (Canada)

^ck NATIONAL KYUSHU CANCER CENTER   (Japan)

^cl NSABP Foundation Inc   (United States)

^cm Nolvadex Adjuvant Trial Organisation   (United Kingdom)

^cn North Central Cancer Treatment Group Rochester   (United States)

^co North Sweden Breast Cancer Group   (Sweden)

^cp North Western British Surgeons   (United Kingdom)

^cq NORTHWICK PARK HOSPITAL   (United Kingdom)

^cr Norwegian Breast Cancer Group   (Norway)

^cs OSLO UNIVERSITY HOSPITAL   (Norway)

^ct NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^cu Oncofrance   (France)

^cv PEDIATRIC ONCOLOGY GROUP OF ONTARIO   (Canada)

^cw Osaka Prefecture University   (Japan)

^cx OSAKA NATIONAL HOSPITAL   (Japan)

^cy CHURCHILL HOSPITAL   (United Kingdom)

^cz Parma Hospital   (Italy)

^da N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

^db Piedmont Oncology Association   (United States)

^dc Prefectural Hospital   (Japan)

^dd UNIVERSITY OF PRETORIA   (South Africa)

^de ROYAL MARSDEN HOSPITAL   (United Kingdom)

^df ST GEORGE S HOSPITAL   (United Kingdom)

^dg ST LUKE S HOSPITAL   (Ireland)

^dh Sardinia Oncology Hospital A Businico   (Italy)

^di SASIB International Trialists   (South Africa)

^dj SASKATCHEWAN CANCER AGENCY   (Canada)

^dk Scandinavian Adjuvant Chemotherapy Study Group   (Norway)

^dl Scottish Cancer Therapy Network   (United Kingdom)

^dm South Swedish Breast Cancer Group   (Sweden)

^dn South East Sweden Breast Cancer Group   (Sweden)

^do South Eastern Cancer Study Group   (United States)

^dp Southwest Oncology Group   (United States)

^dq Stockholm Breast Cancer Study Group   (Sweden)

^dr SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

^ds OSAKO   (Switzerland)

^dt TEL AVIV UNIVERSITY   (Israel)

^du CANCER INSTITUTE HOSPITAL   (Japan)

^dv Toronto Edmonton Breast Cancer Study Group   (Canada)

^dw PRINCESS MARGARET HOSPITAL   (Canada)

^dx PEKING UNION MEDICAL COLLEGE   (China)

^dy SALAH AZAIEZ INSTITUTE   (Tunisia)

^dz UK Multicentre Cancer Chemotherapy Study Group   (United Kingdom)

^ea UK/Asia Collaborative Breast Cancer Group   (United Kingdom)

^eb UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^ec UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^ed Uppsala Örebro Breast Cancer Study Group   (Sweden)

^ee UNIVERSITY OF VIENNA   (Austria)

^ef Wessex Radiotherapy Centre   (United Kingdom)

^eg West Midlands Oncology Association   (United Kingdom)

^eh West of Scotland Breast Trial Group   (United Kingdom)

^ei Western Cancer Study Group   (United States)

^ej UNIVERSITY OF WÜRZBURG   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; GONADORELIN ANTAGONIST; MELPHALAN; METHOTREXATE; PROGESTERONE RECEPTOR; TAMOXIFEN; VINCRISTINE; AROMATASE INHIBITOR; RALOXIFENE; TAXANE DERIVATIVE; TRASTUZUMAB;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG INDUCED CANCER; ELECTROSURGERY; FOLLOW UP; HORMONAL THERAPY; HUMAN; INTERMETHOD COMPARISON; META ANALYSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW; RISK REDUCTION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; ARTICLE; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; EARLY CANCER; OVERALL SURVIVAL; SYSTEMATIC REVIEW; SYSTEMIC THERAPY;

EID: 19344364880     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)66544-0     Document Type: Article

References (22)

1. Anon. Review of mortality results in randomised trials in early breast cancer Lancet 2 1984 1205
2. Early Breast Cancer Trialists' Collaborative Group Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: an overview of 61 randomised trials among 28 896 women N Engl J Med 319 1988 1681 1692
3. Early Breast Cancer Trialists' Collaborative Group Treatment of early breast cancer, vol 1: worldwide evidence, 1985-1990 1990 Oxford University Press Oxford
4. Early Breast Cancer Trialists' Collaborative Group Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women Lancet 339 1992 1 15
5. Early Breast Cancer Trialists' Collaborative Group Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women Lancet 339 1992 71 85
6. Early Breast Cancer Trialists' Collaborative Group Effects of radiotherapy and surgery in early breast cancer: an overview of the randomised trials N Engl J Med 333 1995 1444 1455
7. Early Breast Cancer Trialists' Collaborative Group Ovarian ablation in early breast cancer: overview of the randomised trials Lancet 348 1996 1189 1196
8. Early Breast Cancer Trialists' Collaborative Group Tamoxifen for early breast cancer: an overview of the randomised trials Lancet 351 1998 1451 1467
9. Early Breast Cancer Trialists' Collaborative Group Polychemotherapy for early breast cancer: an overview of the randomised trials Lancet 352 1998 930 942
10. Early Breast Cancer Trialists' Collaborative Group Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials Lancet 355 2000 1757 1770
11. R Peto, MC Pike, P Armitage Design and analysis of randomised clinical trials requiring prolonged observation of each patient, part II: analysis and examples Br J Cancer 35 1977 1 39
12. R Collins, R Peto, R Gray, S Parish Large-scale randomised evidence: trials and overviews DA Warrell TM Cox JD Firth EJ Benz Jr Oxford textbook of medicine 4th edn. 2003 Oxford University Press Oxford 24 36
13. NIH Consensus statements: 114, adjuvant therapy for breast cancer http://odp.od.nih.gov/consensus/cons/114/114_statement.htm (accessed April 7, 2005)
14. K Albain, W Barlow, F O'Malley for the Breast Cancer Intergroup of North America Concurrent versus sequential chemohormonal therapy for postmenopausal receptor-positive breast cancer: mature outcomes and new biologic correlates in phase III intergroup trial 0100 Breast Cancer Res Treat 88 suppl 1 2004 late-breaking abstract 37
15. Swedish Breast Cancer Co-operative Group Randomised trial of 2 versus 5 years of adjuvant tamoxifen in postmenopausal early-stage breast cancer J Natl Cancer Inst 88 1996 1543 1550
16. B Fisher, JP Costantino, DL Wickerham Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study J Natl Cancer Inst 90 1998 1371 1387
17. BW Walsh The effects of estrogen and selective estrogen receptor modulators on cardiovascular risk factors Ann New York Acad Sci 949 2001 163 167
18. R Gray, C Davies, P Perry Tamoxifen for early breast cancer: better late then never Ann Oncol 11 2000 505 507
19. National Cancer Institute Clinical alert: adjuvant therapy of breast cancer - tamoxifen update, November, 1995 http://www.nlm.nih.gov/databases/ alerts/tamoxifen.html (accessed April 7, 2005)
20. G Cocconi Adjuvant chemotherapy in early breast cancer: optimal and suboptimal anthracycline-containing regimens Breast Cancer Res Treat 80 2003 313 320
21. A Mariotto, EJ Feuer, LC Harlan, LW Wun, KA Johnson, J Abrams Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States, 1979-1999 J Natl Cancer Inst 94 2002 1626 1634
22. R Peto, J Boreham, M Clarke, C Davies, V Beral UK and USA breast cancer deaths down 25% in 2000 at ages 20-69 years Lancet 355 2000 1822